Korro Bio, Inc.: 5%+ holders

As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Korro Bio, Inc. The largest reported stake is Lynx1 Capital Management LP's, at 10.7%. 20 filings are on record since August 13, 2025 (Schedule 13G/A, April 2, 2026).

Atlas Venture Fund XI, L.P. also filed stake reports on 3 other companies ↓

Sell to companies like Korro Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-27 · Reporting person: BlackRock, Inc. · Sole voting: 699,169 · Shared voting: 0 · Sole dispositive: 717,813 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
• Filing 2026-08-14 · Reporting person: Balyasny Asset Management L.P. · Sole voting: 951,783 · Shared voting: 0 · Sole dispositive: 951,783 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-04 · Reporting person: Atlas Venture Fund XI, L.P. · Sole voting: 0 · Shared voting: 706,556 · Sole dispositive: 0 · Shared dispositive: 706,556 · SCHEDULE 13D/A, 2026-08-04
• Filed 2026-07-29 · Holder: BlackRock, Inc. · Percent: 5.2% · SCHEDULE 13G
• Filed 2026-05-15 · Holder: Point72 Biotech Private Investments, LLC · Percent: 1.9% · SCHEDULE 13G/A

Korro Bio, Inc. has 20 Schedule 13D or 13G filings on record since 2025-08-13. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: 1 filing or notice, latest 2025-11-12 (layoff filings and notices).

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Korro Bio, Inc. and the warning signs.

See Korro Bio, Inc.'s free Snapshot Watch Korro Bio, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Korro Bio, Inc. and the records around it.

Korro Bio, Inc. elsewhere on the record

• Layoff notices Nov 2025
• Who owns it

Companies that share a holder

• Atlas Venture Fund XI, L.P. also filed stake reports on 3 other companies: DYNE THERAPEUTICS, INC. (Aug 2026), Day One Biopharmaceuticals, Inc. (May 2026), SIONNA THERAPEUTICS, INC. (Oct 2025)
• New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Monte Rosa Therapeutics, Inc. (Jul 2026), Inventiva S.A. (Apr 2026), SpyGlass Pharma, Inc. (Feb 2026)
• Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)

Want the whole picture on Korro Bio, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Korro Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Korro Bio, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   21 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Korro Bio, Inc. by CUSIP 500946108 and gives its principal executive office as 60 FIRST STREET, 2ND FLOOR, SUITE 250, CAMBRIDGE, MA 02141 (SCHEDULE 13G/A, 2026-10-27).

What the percentages are based on

Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 6.60% of the Shares, based on 14,422,571 Shares of common stock outstanding as of May 4, 2026 as reported in the Issuer's Form 10-Q as filed with the Securities Exchange Commision on May 7, 2026.Balyasny Asset Management L.P., SCHEDULE 13G/A, 2026-08-14

Purpose of Transaction (Item 4)

New Enterprise Associates 17, L.P.

NEA 17 acquired the NEA 17 Shares for investment purposes. Information with respect to the 2026 Private Placement set forth in Item 3 above is incorporated herein by reference to the extent responsive to this Item 4. Subject to the Registration Rights Agreement, the 2024 Registration Rights Agreement and the 2026 Registration Rights Agreement (as defined below) and depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17 and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-03-12; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Korro Bio, Inc.

Who owns Korro Bio, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Korro Bio, Inc.: Lynx1 Capital Management LP (10.7%, Schedule 13G/A, filed 2026-04-02), New Enterprise Associates 17, L.P. (9.9%, Schedule 13D/A, filed 2026-03-12), Venrock Healthcare Capital Partners III, L.P. (9.9%, Schedule 13G, filed 2026-03-17), Balyasny Asset Management L.P. (6.6%, Schedule 13G/A, filed 2026-08-14) and Nantahala Capital Management, LLC (6.37%, Schedule 13G, filed 2026-02-13).

Who are the largest shareholders of Korro Bio, Inc.?

By the share each holder's latest filing reports, the largest holders of Korro Bio, Inc. on this page are Lynx1 Capital Management LP (10.7%), New Enterprise Associates 17, L.P. (9.9%) and Venrock Healthcare Capital Partners III, L.P. (9.9%).

When did Lynx1 Capital Management LP buy into Korro Bio, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Lynx1 Capital Management LP on this page is the Schedule 13G, filed 2026-01-05, reporting 7.8%; its latest, Schedule 13G/A filed 2026-04-02, reports 10.7%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 20 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Korro Bio, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Korro Bio, Inc. is mentioned again
• Find former Korro Bio, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes